Innate Pharma reports data from Phase II mycosis fungoides antibody trial

Innate Pharma reports data from Phase II mycosis fungoides antibody trial

Submitted by admin on September 26, 2022 - 10:50am
Source: 
Clinical Trials Arena
News Tags: 
Innate Pharma
mycosis fungoides
clinical trials
lacutamab
Headline: 
Innate Pharma reports data from Phase II mycosis fungoides antibody trial
snippet: 

Innate Pharma has reported data from the ongoing Phase II TELLOMAK clinical trial where its anti-KIR3DL2 antibody, lacutamab (IPH4102), showed clinical responses in advanced mycosis fungoides (MF) patients.

Do Not Allow Advertisers to Use My Personal information